References
1. Ponvert, C., et al., Allergy to beta-lactam antibiotics in children. Pediatrics, 1999. 104 (4): p. e45.
2. Caubet, J.C., et al., The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol, 2011. 127 (1): p. 218-22.
3. Chovel-Sella, A., et al., Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics, 2013.131 (5): p. e1424-7.
4. Gordin, F.M., et al., Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med, 1984. 100 (4): p. 495-9.
5. Peter, J., P. Choshi, and R.J. Lehloenya, Drug hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol, 2019. 19 (4): p. 272-282.
6. Park, B.K., et al., Metabolic activation in drug allergies.Toxicology, 2001. 158 (1-2): p. 11-23.
7. Meng, X., et al., Definition of the Nature and Hapten Threshold of the beta-Lactam Antigen Required for T Cell Activation In Vitro and in Patients. J Immunol, 2017. 198 (11): p. 4217-4227.
8. Pichler, W.J., Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol, 2002. 2 (4): p. 301-5.
9. Pichler, W.J., et al., Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. Int Arch Allergy Immunol, 2015. 168 (1): p. 13-24.
10. Pichler, W.J., The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions. Allergy, 2022.77 (2): p. 404-415.
11. Pichler, W.J., Immune pathomechanism and classification of drug hypersensitivity. Allergy, 2019. 74 (8): p. 1457-1471.
12. Mori, F., et al., Sensitization to amoxicillin/clavulanic acid may underlie severe rashes in children treated for infectious mononucleosis. J Allergy Clin Immunol Pract, 2019. 7 (2): p. 728-731.e1.
13. Dibek Misirlioglu, E., et al., Incidence of Antibiotic-Related Rash in Children with Epstein-Barr Virus Infection and Evaluation of the Frequency of Confirmed Antibiotic Hypersensitivity. International Archives of Allergy and Immunology, 2018. 176 (1): p. 33-38.
14. Hari, Y., et al., T cell involvement in cutaneous drug eruptions. Clin Exp Allergy, 2001. 31 (9): p. 1398-408.
15. Pichler, W.J., Delayed drug hypersensitivity reactions. Ann Intern Med, 2003. 139 (8): p. 683-93.
16. Yawalkar, N., et al., Elevated serum levels of interleukins 5, 6, and 10 in a patient with drug-induced exanthem caused by systemic corticosteroids. J Am Acad Dermatol, 1998. 39 (5 Pt 1): p. 790-3.
17. Schnyder, B., et al., T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy, 1998. 28 (11): p. 1412-7.
18. Yawalkar, N., et al., Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy, 2000.30 (6): p. 847-55.
19. Hertl, M., F. Jugert, and H.F. Merk, CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol, 1995. 132 (2): p. 215-20.
20. Kuechler, P.C., et al., Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy, 2004. 59 (6): p. 613-22.
21. Le Cleach, L., et al., Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol, 2000.119 (1): p. 225-30.
22. Mitamura, Y., et al., Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients.Allergy, 2022. 77 (2): p. 595-608.
23. Nassif, A., et al., Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol, 2004.114 (5): p. 1209-15.
24. Villani, A.P., et al., Massive clonal expansion of polycytotoxic skin and blood CD8(+) T cells in patients with toxic epidermal necrolysis. Sci Adv, 2021. 7 (12).
25. Phillips, E. and S. Mallal, Drug hypersensitivity in HIV.Curr Opin Allergy Clin Immunol, 2007. 7 (4): p. 324-30.
26. Yawalkar, N., et al., Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol, 2000. 106 (6): p. 1171-6.
27. Hari, Y., et al., Distinct serum cytokine levels in drug- and measles-induced exanthema. Int Arch Allergy Immunol, 1999.120 (3): p. 225-9.
28. Pichler, W.J., et al., High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol, 1997.113 (1-3): p. 177-80.
29. Ahmad, I., et al., Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2011.17 (11): p. 1673-8.
30. Martin, S.F., New concepts in cutaneous allergy. Contact Dermatitis, 2015. 72 (1): p. 2-10.
31. Sacco, K.A., et al., Clinical outcomes following inpatient penicillin allergy testing: A systematic review and meta-analysis.Allergy, 2017. 72 (9): p. 1288-1296.
32. Klenerman, P. and A. Oxenius, T cell responses to cytomegalovirus. Nat Rev Immunol, 2016. 16 (6): p. 367-77.
33. Adam, J., et al., Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses. PLoS One, 2014. 9 (4): p. e95339.
34. Singh, J., et al., The resurgence of covalent drugs. Nat Rev Drug Discov, 2011. 10 (4): p. 307-17.
35. Anci, E., et al., Viral Infections and Cutaneous Drug-Related Eruptions. Front Pharmacol, 2020. 11 : p. 586407.
36. Brockow, K., G. Wurpts, and A. Trautmann, Patients with questionable penicillin (beta-lactam) allergy: Causes and solutions.Allergol Select, 2022. 6 : p. 33-41.
37. Patel, B.M., Skin rash with infectious mononucleosis and ampicillin. Pediatrics, 1967. 40 (5): p. 910-1.
38. Jappe, U., Amoxicillin-induced exanthema in patients with infectious mononucleosis: allergy or transient immunostimulation?Allergy, 2007. 62 (12): p. 1474-5.
39. Pinto Gouveia, M., et al., Overlap between maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms among cutaneous adverse drug reactions in a dermatology ward. Br J Dermatol, 2016. 175 (6): p. 1274-1283.
40. Schmid-Grendelmeier, P., et al., Benralizumab for severe DRESS in two COVID-19 patients. J Allergy Clin Immunol Pract, 2021.9 (1): p. 481-483.e2.
41. Herman, A., et al., Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19. J Eur Acad Dermatol Venereol, 2020. 34 (12): p. e768-e700.
42. Ramirez, G.A., et al., Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. Clin Microbiol Infect, 2021. 27 (8): p. 1190-1192.
43. Grandolfo, M., et al., Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era. Dermatol Ther, 2020. 33 (4): p. e13499.
44. Schulte-Schrepping, J., et al., Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 2020. 182 (6): p. 1419-1440.e23.
45. Zhou, L., et al., Drug allergies documented in electronic health records of a large healthcare system. Allergy, 2016.71 (9): p. 1305-13.
46. Khan, D.A., S.R. Knowles, and N.H. Shear, Sulfonamide Hypersensitivity: Fact and Fiction. J Allergy Clin Immunol Pract, 2019.7 (7): p. 2116-2123.
47. von Greyerz, S., et al., Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. J Immunol, 1999. 162 (1): p. 595-602.
48. Watkins, S. and W.J. Pichler, Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition. PLoS One, 2013. 8 (10): p. e76211.
49. Jaffe, H.S., et al., Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet, 1983. 2 (8359): p. 1109-11.
50. Eliaszewicz, M., et al., Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol, 2002. 47 (1): p. 40-6.
51. Yang, C., et al., HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4⁺ T cells. J Am Acad Dermatol, 2014. 70 (6): p. 1096-102.
52. Seishima, M., et al., Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol, 2006. 155 (2): p. 344-9.
53. Tohyama, M., et al., Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol, 2007. 157 (5): p. 934-40.
54. Shiohara, T., et al., The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol, 2007. 156 (5): p. 1083-4.
55. Shiohara, T., M. Inaoka, and Y. Kano, Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int, 2006. 55 (1): p. 1-8.
56. Kano, Y., et al., Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol, 2006. 155 (2): p. 301-6.
57. Husain, Z., B.Y. Reddy, and R.A. Schwartz, DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol, 2013.68 (5): p. 693.e1-14; quiz 706-8.
58. Mizukawa, Y., et al., Predictive biomarkers for cytomegalovirus reactivation before and after immunosuppressive therapy: A single-institution retrospective long-term analysis of patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic syndrome (DRESS). Int J Infect Dis, 2020.100 : p. 239-246.
59. Shiohara, T. and Y. Mizukawa, Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int, 2019. 68 (3): p. 301-308.
60. Yun, J., et al., Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol, 2014. 192 (7): p. 2984-93.
61. Mennicke, M., et al., Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant, 2009. 9 (9): p. 2197-202.
62. Koch, S., et al., Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci, 2007.1114 : p. 23-35.
63. Liu, T., et al., Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol, 2001. 75 (22): p. 11178-84.
64. Croft, M., L.M. Bradley, and S.L. Swain, Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol, 1994. 152 (6): p. 2675-85.
65. Yoshikawa, T., et al., Human herpesvirus 6 reactivation and inflammatory cytokine production in patients with drug-induced hypersensitivity syndrome. J Clin Virol, 2006. 37 Suppl 1 : p. S92-6.
66. Beeler, A., et al., Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol, 2006. 117 (2): p. 455-62.
67. Pritchett, J.C., R.M. Nanau, and M.G. Neuman, The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation. Int J Hepatol, 2012. 2012 : p. 723062.
68. Wuillemin, N., et al., The Activation Pattern of Drug-Reacting T Cells Has an Impact on the Clinical Picture of Hypersensitivity Reactions. Front Allergy, 2022. 3 : p. 804605.
69. Shiohara, T., et al., Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). Expert Opin Drug Metab Toxicol, 2017. 13 (7): p. 701-704.
70. Jörg, L., et al., Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS). Clin Transl Allergy, 2020.10 (1): p. 52.
71. Pichler, W.J., et al., Multiple Drug Hypersensitivity. Int Arch Allergy Immunol, 2017. 172 (3): p. 129-138.